A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Part of paid clinical trials in Lancaster, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06869551
Phase
PHASE3
Status
Recruiting

Conditions

  • Juvenile Psoriatic Arthritis

Eligibility Criteria

Sex
ALL
Age
5 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days
  • Placebo — OTHER
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Key Dates

Start date
Mar 13, 2025
Status verified
Jun 2026
Primary completion
Mar 6, 2030
Completion
Mar 4, 2031

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Placebo Comparator: Arm B

Primary Outcome Measure

Time to first flare during the withdrawal period [ Time Frame: From week 16 up to week 42 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
  • First line of the email MUST contain NCT # and Site #.

Locations (7)

FacilityCityStateZIPSite coordinators
Local Institution - 0038LancasterCalifornia93534-
Local Institution - 0020ChicagoIllinois60611-
Local Institution - 0023IndianapolisIndiana46202-
Local Institution - 0059North New Hyde ParkNew York11040-
Local Institution - 0065CincinnatiOhio45229-
Local Institution - 0066ClevelandOhio44109-
Local Institution - 0036AustinTexas78723-

Find similar trials in Lancaster, CA

Related Studies